FDA approves clinical trial application for CS231295 tablets
August 2, 2025
Source: drugdu
59
On July 31, Chipscreen Bio announced that its wholly-owned subsidiary, Chipscreen Biotech (USA), Inc., received FDA approval for a Phase I clinical trial of CS231295 for the treatment of advanced solid tumors. CS231295 is a brain-penetrating, selective inhibitor of Aurora B. Its superior blood-brain barrier penetration offers significant therapeutic advantages for primary and metastatic brain tumors. Currently, no other drug of this design has entered clinical trials globally.
Brain tumors, due to the blood-brain barrier, make it difficult for most drugs to effectively enter the central nervous system, and have long been considered a "forbidden zone" in anti-tumor drug development. Chipscreen Biopharmaceuticals' CS231295 has received FDA approval for clinical trials, demonstrating its differentiated innovation capabilities in brain tumor treatment.
Source：https://www.yicai.com/news/102752034.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Investigation raises concerns over tooth stem cell banking claims August 21, 2025
- Seniors Neglecting Steps To Protect Heart Health, Study Says August 21, 2025
- Pfizer’s $5.4 billion gamble fails August 21, 2025
- InnoCare Pharma’s new anticancer drug Mesutoclax completes first patient dosing in clinical trial August 21, 2025
- Novartis’ innovative drug Noradrena approved for IgA nephropathy in China August 21, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
